Cardiol Therapeutics (TSE:CRDL) Trading Down 17.2% – Time to Sell?

Cardiol Therapeutics Inc. (TSE:CRDL)’s stock price was down 17.2% during mid-day trading on Monday . The company traded as low as C$1.24 and last traded at C$1.25. Approximately 480,129 shares traded hands during mid-day trading, an increase of 342% from the average daily volume of 108,711 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Price Performance

The company has a debt-to-equity ratio of 1.59, a current ratio of 2.49 and a quick ratio of 6.84. The company has a 50 day moving average price of C$1.50 and a 200 day moving average price of C$1.65. The firm has a market cap of C$129.00 million, a PE ratio of -3.15 and a beta of 1.31.

Cardiol Therapeutics (TSE:CRDL) last posted its quarterly earnings data on Thursday, November 13th. The company reported C($0.12) earnings per share for the quarter. Sell-side analysts expect that Cardiol Therapeutics Inc. will post -0.49 EPS for the current fiscal year.

About Cardiol Therapeutics

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.